Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FBTA05 with DLI for Relapsed CD20+ Malignancies Post-Transplant
NCT01138579Phase 2Withdrawn
- Sponsor
- Technical University of Munich
- Start
- Aug 2010
- Primary completion
- May 2015
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of FBTA05 in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Technical University of Munich. Planned start Aug 2010; status: withdrawn.
02
Drugs
FBTA05
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01138579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138579.